Evidence mapPaperPMID 40001465Full record

ReviewBiomolecules2025

Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature.

Hesham Sheashaa, Hana Mousa, Mohammed Tiseer Abbas, Juan M Farina, Kamal Awad, Milagros Pereyra, Isabel G Scalia, Nima Baba Ali, Niloofar Javadi, Nadera N Bismee and 7 more

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hesham SheashaaDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0009-0000-4740-5388
Hana MousaDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Mohammed Tiseer AbbasDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0009-0004-7212-435X
Juan M FarinaDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0000-0002-5824-8485
Kamal AwadDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Milagros PereyraDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0000-0003-4695-8436
Isabel G ScaliaDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0000-0002-6459-9767
Nima Baba AliDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0009-0004-3979-0609
Niloofar JavadiDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Nadera N BismeeDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0009-0001-7502-0992
Sogol Attaripour EsfahaniDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Omar IbrahimDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0009-0003-2530-7850
Fatmaelzahraa AbdelfattahDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0009-0008-0758-1086
Ramzi IbrahimDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Mahmoud AbdelnabiDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Chadi AyoubDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Reza ArsanjaniDepartment of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.ORCID 0000-0001-7081-4286

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein(a) [Lp(a)] is a well-established causal risk factor for cardiovascular diseases (CVDs), as reported by multiple Mendelian randomization studies and large epidemiological studies. When elevated Lp(a) is combined with other risk factors, most notably elevated low-density lipoprotein cholesterol (LDL-C), a synergistic atherogenic effect has been reported. However, the current literature is conflicting regarding how Lp(a) interacts in the context of controlled LDL-C levels (e.g., <70 mg/dL) and whether reducing LDL-C can modify the atherogenic effect of Lp(a). In some studies, elevated Lp(a) was still significantly associated with a higher risk of cardiovascular events, despite controlled levels of LDL-C. In contrast, multiple studies have reported attenuation of the cardiovascular risk mediated by elevated Lp(a) with lower LDL-C levels. Moreover, the relationship between Lp(a) and triglycerides, high-density lipoprotein, and very low-density lipoprotein remains unclear. In this literature review, we summarize and discuss the current evidence regarding the interactions between Lp(a) and other lipid molecules, how they contribute to the pathogenesis of CVD, and future perspectives, particularly in the current era where promising targeted Lp(a)-lowering therapies are under development.

Indexed as

Cardiovascular DiseasesLipoprotein(a)AnimalsCholesterol, LDLHumansTriglyceridesCholesterol, LDLLipoprotein(a)Triglyceridesatherosclerosiscardiovascularinteractionlipoprotein(a)mortalityrisk factor

Identifiers

PMID40001465
PMCPMC11853184

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.